PubRank

S R Petteway

Author PubWeight™ 47.06‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science 1986 6.33
2 Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. Proc Natl Acad Sci U S A 1991 4.40
3 Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci U S A 1996 3.07
4 Human chromosome 12 is required for elevated HIV-1 expression in human-hamster hybrid cells. Science 1989 2.03
5 Polymorphism of the 3' open reading frame of the virus associated with the acquired immune deficiency syndrome, human T-lymphotropic virus type III. Nucleic Acids Res 1985 2.01
6 HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. Biochemistry 1996 1.91
7 Purification and properties of thiol beta-lactamase. A mutant of pBR322 beta-lactamase in which the active site serine has been replaced with cysteine. J Biol Chem 1984 1.88
8 Expression and site-specific mutagenesis of the poliovirus 3C protease in Escherichia coli. Proc Natl Acad Sci U S A 1986 1.76
9 Alteration of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain. AIDS Res Hum Retroviruses 1991 1.50
10 A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 2001 1.49
11 Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage. J Virol 1992 1.46
12 V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity. Virology 1992 1.35
13 Antibodies from human immunodeficiency virus-infected individuals bind to a short amino acid sequence that elicits neutralizing antibodies in animals. AIDS Res Hum Retroviruses 1989 1.35
14 Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. AIDS Res Hum Retroviruses 1987 1.27
15 Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells. Antimicrob Agents Chemother 1992 1.24
16 Formation of poliovirus RNA polymerase 3D in Escherichia coli by cleavage of fusion proteins expressed from cloned viral cDNA. Virology 1987 1.20
17 Effect of a single amino acid substitution in the V3 domain of the human immunodeficiency virus type 1: generation of revertant viruses to overcome defects in infectivity in specific cell types. J Virol 1994 1.02
18 The effects of hybrid ribosome-binding-site variants on the expression of human interferon-beta in Escherichia coli. Gene 1985 1.00
19 Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. J Virol Methods 2000 1.00
20 Antibodies reactive with human immunodeficiency virus gag-coded antigens (gag reactive only) are a major cause of enzyme-linked immunosorbent assay reactivity in a blood donor population. J Clin Microbiol 1988 0.96
21 Antiretroviral activities of protease inhibitors against murine leukemia virus and simian immunodeficiency virus in tissue culture. Antimicrob Agents Chemother 1993 0.84
22 Human chromosome-dependent and -independent pathways for HIV-2 trans-activation. AIDS Res Hum Retroviruses 1991 0.84
23 Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates. Biologicals 2002 0.83
24 In vivo modulation of hematopoiesis by a novel hematoregulatory peptide. Exp Hematol 1994 0.81
25 Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection. Antiviral Res 1993 0.81
26 Stable indicator cell lines exhibiting HIV-1 tat function. AIDS Res Hum Retroviruses 1989 0.80
27 Efficacy of the hematoregulatory peptide SK&F 107647 in experimental systemic Candida albicans infections in normal and immunosuppressed mice. Immunopharmacology 1994 0.78
28 Critical factors influencing prion inactivation by sodium hydroxide. Vox Sang 2006 0.76
29 Pathogen safety of manufacturing processes for biological products: special emphasis on KOGENATE Bayer. Haemophilia 2002 0.76
30 Ensuring the pathogen safety of intravenous immunoglobulin and other human plasma-derived therapeutic proteins. J Allergy Clin Immunol 2001 0.76
31 Chemical synthesis and expression of a gene encoding HIV-1 TAT protein. Biochem Biophys Res Commun 1989 0.75
32 Potent inhibition of HIV type 1 infection of mononuclear phagocytes by synthetic peptide analogs of HIV type 1 protease substrates. AIDS Res Hum Retroviruses 1996 0.75
33 Biochemistry and structure of picornavirus proteases. Prog Clin Biol Res 1985 0.75
34 Effects of SKF 108922, an HIV-1 protease inhibitor, on retrovirus replication in mice. Antiviral Res 1996 0.75